Inflammation-induced shift in spinal GABA(A) signaling is associated with a tyrosine kinase-dependent increase in GABA(A) current density in nociceptive afferents.
To account for benzodiazepine-induced spinal analgesia observed in association with an inflammation-induced shift in the influence of the GABA(A) receptor antagonist gabazine on nociceptive threshold, the present study was designed to determine whether persistent inflammation is associated with the upregulation of high-affinity GABA(A) receptors in primary afferents. The cell bodies of afferents innervating the glabrous skin of the rat hind paw were retrogradely labeled, acutely dissociated, and studied before and after the induction of persistent inflammation. A time-dependent increase in GABA(A) current density was observed that was more than twofold by 72 h after the initiation of inflammation. This increase in current density included both high- and low-affinity currents and was restricted to neurons in which GABA increased intracellular Ca(2+). No increases in GABA(A) receptor subunit mRNA or protein were detected in whole ganglia. In contrast, the increased current density was completely reversed by 20-min preincubation with the tyrosine kinase inhibitor genistein and partially reversed with the Src kinase inhibitor PP2. Genistein reversal was partially blocked by the dynamin inhibitor peptide P4. Changes in nociceptive threshold following spinal administration of genistein and muscimol to inflamed rats indicated that the pronociceptive actions of muscimol observed in the presence of inflammation were reversed by genistein. These results suggest that persistent changes in relative levels of tyrosine kinase activity following inflammation provide not only a sensitive way to dynamically regulate spinal nociceptive signaling but a viable target for the development of novel therapeutic interventions for the treatment of inflammatory pain.
Department of Neural and Pain Sciences, University of Maryland, Baltimore School of Dentistry, Baltimore, Maryland, USA.
Yi
Y
Zhu
Shiv
S
Dua
Michael S
MS
Gold
D000200:Action Potentials / Q000187:drug effects / Q000502:physiology; D000818:Animals; D002118:Calcium / Q000378:metabolism; D005620:Freund's Adjuvant / Q000633:toxicity; D058785:GABA-A Receptor Agonists / Q000494:pharmacology; D058787:GABA-A Receptor Antagonists / Q000494:pharmacology; D059330:GABAergic Neurons / Q000378:metabolism / Q000502:physiology*; D005727:Ganglia, Spinal / Q000502:physiology; D019833:Genistein / Q000494:pharmacology; D007249:Inflammation / Q000139:chemically induced; D008297:Male; D009118:Muscimol / Q000494:pharmacology; D009619:Nociceptors / Q000378:metabolism / Q000502:physiology*; D009842:Oligopeptides / Q000494:pharmacology; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism*; D051381:Rats; D017207:Rats, Sprague-Dawley; D011963:Receptors, GABA-A / Q000235:genetics / Q000378:metabolism*; D012684:Sensory Thresholds; D015398:Signal Transduction; D015854:Up-Regulation
D058785:GABA-A Receptor Agonists; D058787:GABA-A Receptor Antagonists; D009842:Oligopeptides; D011963:Receptors, GABA-A; C560821:peptide P4; D009118:Muscimol; D005620:Freund's Adjuvant; D019833:Genistein; D011505:Protein-Tyrosine Kinases; D002118:Calcium